United Therapeutics CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
United Therapeutics Corporation has released its 2026 Proxy Statement, detailing proposals for the upcoming Annual Meeting of Shareholders, including director elections, executive compensation, and stock incentive plans.
NASDAQ
United Therapeutics Corporation has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: United Therapeutics Corporation Announces 2025 Annual Meeting and Executive Compensation Details
United Therapeutics Corporation files its definitive proxy statement for the 2025 Annual Meeting of Shareholders, detailing board nominations, executive compensation, and other important corporate governance matters.
NASDAQ
United Therapeutics Corporation has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
NASDAQ
DEF 14A: United Therapeutics Aims for $4 Billion Revenue Run Rate by Mid-Decade, Proxy Statement Reveals
United Therapeutics' proxy statement highlights strong 2023 financial performance and ambitious goals for future growth, including a $4 billion revenue run rate by mid-decade.